COMPANY

  1. COMPANY

FOR THE NEW ERA OF MEDICINE

CREATION
We develope new technologies for healthcare
FUSION
We integrate new technologies with existing ones
PASSION
We devote all our passion

PROFILE

Company Name Cellspect Co., Ltd
Address
Head Office MAP

Morioka New Technology Business Creation Support Center, 1-10-82 Kitaiioka, Morioka, Iwate 020-0857 JAPAN
E-mail : info@cellspect.com

Tokyo Office MAP

7F, Otemachi Park Building, 1-1-1 Otemachi, Chiyoda-ku, Tokyo, 100-0004 JAPAN

R&D Center MAP

The 21st Century Plaza Research Center, 2-1-40 Takamori, Izumi-ku Sendai, Miyagi 981-3203 JAPAN

Representative
CEO
Takuya Iwabuchi
CFO
Kazuhiro Koide
Outside Director
                             
Keiji Katano(CEO of Icomes Lab Co.,Ltd.)
                             
Supervisor
                             
Mieko Mio(Lawyer)
Capital 457,900,000 JPY (capital reserve included)
Main Bank The Bank of Iwate, Ltd., Mizuho Bank, Japan Finance Corporation (JFC), The Kita-nippon Bank, Ltd.
Major shareholder Mizuho Capital Co., Ltd., Iwagin Jigyo Venture Capital Co.,Ltd. (IJVC), Mitsubishi UFJ Capital Co., Ltd.
Business Overview Next generation primary care solution, Transvaginal Endometriotic cyst Analysis System, Liquid biopsy and personalized cancer medicine, Health tech and Health data business etc.
Number of employees 35 (as of Sep., 2017)

ACCESS

Head Office

Google Map

Tokyo Office

Google Map

R&D Center

Google Map

HISTORY

  • Establishment of CellSpect Co., Ltd. headquarter in Morioka

  • H26 Iwate strategic R&D promotion project

    Development of highly accurate cell picking system for detection of circulating tumor cells

  • Eligibility of special finance support capital loan (national life corporation) from Japan Finance Corporation (JFC)

    Development of diagnostic marker of endometriosis-associated ovarian carcinoma (EAOC)

  • Capital (capital reserve included) increase through third-party investors in series A round (capital reached 157.8 million yen)

    Mizuho Capital Co., Ltd., Iwagin Jigyo Venture Capital Co.,Ltd. (IJVC)

  • Selected as H28 Strategic Core Technology Advancement Program (Supporting Industry Program) by Ministry of Economy, Trade and Industry

    Development of low invasive optical transvaginal probe for diagnosis of EAOC

  • Eligibility of special finance support capital loan (small and medium enterprises) from Japan Finance Corporation (JFC)

CONTACT

  • ※E-mails sent from us to customers are confidencial. Please do not reprint part or all of the content of answer either for secondary use. We may not be able to answer when there is an error in the e-mail address or when a system fault occurs and etc.
  • ※Regarding inquiries, we will reply within 3 business days. If there is no contact after 3 business days, please contact us again and we are sorry for the inconvenience.